A venture capital investor needed a reality check on a clinical stage cancer biologic prior to a proposed $10m investment.
We conducted the analysis within four days, which included a review of a comprehensive data room encompassing preclinical, clinical, regulatory, manufacturing and IP matters. Our report identified the areas of key risk in the project and suggested how to mitigate them.